[BLUE] bluebird bio, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Biotechnology: Biological Products (No Diagnostic Substances)

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 64.65 Change: 2.15 (3.44%)
Ext. hours: Change: 0 (0%)

chart BLUE

Refresh chart

Strongest Trends Summary For BLUE

BLUE is in the medium-term down -17% below S&P in 1 month. In the long-term up 119% in 4 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: bluebird bio, Inc., a clinical-stage biotechnology company, focuses on developing gene therapies for severe genetic and orphan diseases. The company?s advanced product candidate is Lenti-D, which is in phase II/III studies for the treatment of childhood cerebral adrenoleukodystrophy, a rare, hereditary neurological disorder affecting young boys; and LentiGlobin that is in phase I/II studies for the treatment of beta-thalassemia major and severe sickle cell disease in France, as well as a second phase I/II studies with LentiGlobin for the treatment of beta-thalassemia major in the United States. bluebird bio, Inc. has a strategic collaboration with Celgene Corporation to discover, develop, and commercialize disease-altering gene therapies in oncology. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was founded in 1992 and is headquartered in Cambridge, Massachusetts.

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS-7.22 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 0.14% Sales Growth - Q/Q-0.66% P/E-15.06
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-11.78% ROE-13.25% ROI
Current Ratio8.11 Quick Ratio Long Term Debt/Equity Debt Ratio0.09
Gross Margin Operating Margin-294.47% Net Profit Margin-247.3% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities2.46 M Cash From Investing Activities-192.98 M Cash From Operating Activities-24.16 M Gross Profit
Net Profit-24.79 M Operating Profit-24.93 M Total Assets533.82 M Total Current Assets340.84 M
Total Current Liabilities42.01 M Total Debt Total Liabilities59.32 M Total Revenue6.34 M
Technical Data
High 52 week197 Low 52 week91.25 Last close141 Last change-1.4%
RSI28.94 Average true range5.96 Beta1.77 Volume513.89 K
Simple moving average 20 days-5.97% Simple moving average 50 days-5.32% Simple moving average 200 days2.08%
Performance Data
Performance Week4.04% Performance Month-7.86% Performance Quart11.67% Performance Half26.38%
Performance Year-18.61% Performance Year-to-date42.14% Volatility daily2.85% Volatility weekly6.36%
Volatility monthly13.04% Volatility yearly45.17% Relative Volume135.56% Average Volume495.42 K
New High New Low

News

2019-05-25 12:30:42 | Marshall Wace’s Latest Moves

2019-05-19 07:00:00 | Top 5 New Drug Launches of 2019 -- and the Biotech Stocks That Could Win Big

2019-05-16 09:12:00 | bluebird bio to Present New Data from Clinical Studies of LentiGlobin™ Gene Therapy for Transfusion-Dependent ?-thalassemia TDT and LentiGlobin Gene Therapy for Sickle Cell Disease SCD at the 24th EHA Congress

2019-05-15 14:10:36 | Bluebird Bio's Near-Term Product Launches Pose Risks, Wedbush Says In Downgrade

2019-05-15 10:49:00 | Bluebird Bio’s Pricing Plan Worries One Biotech Analyst. Here’s Why.

2019-05-09 06:30:00 | bluebird bio’s Analyst Day Highlights Commercial Path to Patients and Research Engine Focused on Next-Generation Gene and Cell Therapies

2019-05-08 08:12:00 | bluebird bio Flies Forward

2019-05-07 08:04:37 | See what the IHS Markit Score report has to say about bluebird bio Inc.

2019-05-06 11:50:03 | bluebird's BLUE Loss Wider Than Expected, Revenues Down Y/Y

2019-05-03 08:00:00 | bluebird bio Announces Investor Events in May

2019-05-02 18:45:10 | Bluebird Bio BLUE Reports Q1 Loss, Tops Revenue Estimates

2019-05-02 17:40:44 | Bluebird: 1Q Earnings Snapshot

2019-05-02 16:05:00 | bluebird bio Reports First Quarter 2019 Financial Results and Highlights Operational Progress

2019-05-01 17:01:00 | Celgene Corporation and bluebird bio Announce Results from Ongoing Multicenter Phase 1 Study of bb2121 anti-BCMA CAR T Cell Therapy in Patients with Multiple Myeloma Published in New England Journal of Medicine

2019-05-01 08:00:00 | bluebird bio Appoints Joanne Smith-Farrell, Ph.D., to Chief Business Officer

2019-04-30 15:18:51 | 5 Biotech Stocks for a Long-Lived Portfolio

2019-04-30 09:15:01 | Small Gains Still Bring New Highs

2019-04-29 08:01:00 | 20 High-Growth Stocks For The Next 20 Years

2019-04-28 22:47:02 | Is a Beat in the Cards for Molina's MOH Earnings in Q1?

2019-04-27 07:33:00 | How a Medicare Rule Change Could Bring CAR-T Stocks Back to Life

2019-04-26 11:48:03 | Universal Health UHS Q1 Earnings, Revenues Miss Estimates

2019-04-26 11:42:03 | What's in Store for HCA Healthcare's HCA Q1 Earnings?

2019-04-26 11:38:03 | Is a Beat in Store for WellCare Health's WCG Q1 Earnings?

2019-04-25 14:20:03 | Why bluebird bio, Inc.'s NASDAQ:BLUE CEO Pay Matters To You

2019-04-25 11:55:03 | Tenet Healthcare THC to Post Q1 Earnings: What's in Store?

2019-04-24 11:25:03 | Anthem's ANTM Q1 Earnings Beat Estimates, Improve Y/Y

2019-04-24 10:33:02 | Bluebird Bio BLUE Expected to Beat Earnings Estimates: Should You Buy?

2019-04-24 05:46:31 | Ahead of 1st drug approval, bluebird CEO's pay triples to $24M

2019-04-23 18:20:00 | SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Breaches of Fiduciary Duty by the Certain Officers and Directors of bluebird bio, Inc.

2019-04-22 15:09:07 | Did Hedge Funds Drop The Ball On bluebird bio Inc BLUE ?

2019-04-22 13:54:15 | This Is Why You Shouldn’t Count Regeneron Stock Out

2019-04-19 14:48:00 | Top Gene-Sequencing Stocks for 2019

2019-04-18 14:45:40 | Cambridge's bluebird bio expanding Kendall Square HQ

2019-04-17 17:15:15 | Here's Why Shares of bluebird bio Slumped Today

2019-04-15 14:00:15 | Four Companies Could Power The New Genomics ETF

2019-04-09 10:52:00 | Why bluebird bio Could Deliver Miracles to Genetic Disease Patients

2019-04-09 10:50:22 | See what the IHS Markit Score report has to say about bluebird bio Inc.

2019-04-09 09:53:00 | 5 Stocks in the Age of Miracles

2019-04-08 18:11:10 | Celgene & Acceleron Submit BLA for Luspatercept to the FDA

2019-04-07 09:05:00 | 3 High-Growth Genomics Stocks You Can Buy

2019-03-31 11:01:00 | 2 Blockbuster Gene Therapy Programs to Watch in 2019

2019-03-29 09:33:12 | Most Analysts Have Given bluebird bio Positive Ratings in March

2019-03-29 07:47:42 | EMA panel recommends approval of Bluebird Bio's first gene therapy

2019-03-29 07:44:00 | bluebird bio Receives Positive Opinion from CHMP for ZYNTEGLO™ autologous CD34+ cells encoding ?A-T87Q-globin gene Gene Therapy for Patients 12 Years and Older with Transfusion-Dependent ?-Thalassemia TDT Who Do Not Have ?0/?0 Genotype

2019-03-26 17:15:09 | Celgene CELG Submits NDA for MS Drug to FDA for Review

2019-03-26 08:55:56 | See what the IHS Markit Score report has to say about bluebird bio Inc.

2019-03-25 08:24:04 | Massachusetts concern details plan to hire new workers in Durham

2019-03-23 09:30:01 | Why Is Bluebird BLUE Up 15.3% Since Last Earnings Report?

2019-03-22 08:00:00 | bluebird bio Opens State-of-the-Art Gene and Cell Therapy Manufacturing Facility in Durham, North Carolina

2019-03-12 10:30:05 | See what the IHS Markit Score report has to say about bluebird bio Inc.